The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

The risk of dying from the most common form of primary liver cancer is approximately 30% higher for patients with low ...

RT-PCR test quantifying CP mRNA in blood can detect hepatocellular carcinoma early—especially in AFP-negative cases—offering ...

It is a leading cause of liver cancer, responsible for 50%–80% of hepatocellular carcinoma cases globally.1 Chronic HBV infection leads to the integration of HBV DNA into the host genome ...

There is no standard of care for fibrolamellar liver cancer, no targeted therapies. But that may be changing, thanks to ...

Hepatocellular carcinoma (HCC), the most common form of liver cancer, continues to pose a significant global health challenge ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...